Rational peptide design for inhibition of the KIX-MLL interaction.

Area of Science:

• Biochemistry
• Molecular Biology
• Drug Discovery

Background:

• The kinase-inducible domain interacting (KIX) domain, part of CREB-binding protein, is implicated in leukemia, cancer, and viral diseases.
• KIX domain interactions are crucial in transcriptional regulation, making it a target for therapeutic intervention.
• Inhibiting protein-protein interactions involving KIX is a key strategy in drug development.

Purpose of the Study:

• To rationally design and characterize a high-affinity peptide inhibitor targeting the KIX domain.
• To identify specific mutations in the MLL transactivation domain (TAD) that enhance binding to the KIX domain.
• To evaluate the inhibitory potential of designed peptides on the KIX-MLL interaction.

Main Methods:

• Utilized Rosetta software for theoretical saturation mutagenesis of the MLL TAD peptide.
• Selected mutant peptides with enhanced helical propensity for experimental validation.
• Measured binding affinity and inhibitory activity of designed peptides against the KIX domain.

Main Results:

• Identified the T2857W mutant of the MLL TAD peptide with the highest binding affinity for the KIX domain.
• The T2857W peptide demonstrated potent inhibition of the KIX-MLL interaction.
• Achieved the highest affinity for KIX among reported inhibitors targeting the MLL binding site.

Conclusions:

• The rationally designed T2857W MLL TAD peptide is a potent inhibitor of KIX domain interactions.
• This study presents a successful strategy for developing helical peptides to inhibit disease-associated protein-protein interactions.
• The findings offer a new therapeutic avenue for diseases involving KIX-mediated pathways.